IBD Medicine - Search News

Teva, Sanofi and IBD

Teva, Sanofi say drug to treat IBD met primary targets

Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and Crohn's disease showed it had met primary goals. Teva and Sanofi said last year they would collaborate on developing a treatment for inflammatory bowel disease (IBD),

biopharma-reporter · 1d

Teva and Sanofi’s IBD drug hits Phase 2 targets

The anti-TL1A antibody allowed significantly more inflammatory bowel disease (IBD) patients to go into remission than those taking placebo treatment.

Wall Street Journal · 1d

Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment

Duvakitug was generally well tolerated across patient groups and showed similar rates of treatment-emergent adverse events, according to the companies.

Managed Healthcare Executive5d

For People With IBD, It's an Insurance Is an Obstacle Course to Medications and Care, Foundation Survey Finds

More than half (62.7%) of respondents reported facing financial barriers to obtaining their IBD medication.

Everyday Health8d

5 of the Best Inflammatory Bowel Disease (IBD) Support Organizations

Ira Daniel Breite, MD, is a board-certified internist and gastroenterologist. He is an associate professor at the Icahn ...

What to Know About Vagus Nerve Stimulation for IBD

The trial was investigating the use of vagus nerve stimulation (VNS) for inflammatory bowel disease (IBD), an autoimmune ...

MedPage Today2d

Longer Admissions for IBD Flares Linked to VTE Risk

ORLANDO -- Longer hospitalization for flares of inflammatory bowel disease (IBD) was linked to greater risk of subsequent ...

Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease

Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s diseasePrimary endpoints met in ...

GEN8d

Insilico Details AI-Designed IBD Candidate’s Path to Nomination

ISM5411 is designed to directly regulate the intestinal immune microenvironment so that the drug simultaneously reduces the gut inflammation seen in IBD while also promoting the repair of the ...

News Medical on MSN2d

NYU Langone IBD Center celebrates two years of transforming lives

A complex, chronic, and debilitating condition, inflammatory bowel disease (IBD) affects roughly 3 million Americans, including those with Crohn's disease and ulcerative colitis.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results